出版物和演讲
| 活动/出版物 | 日期 | 主题 |
|---|---|---|
| American Journal of Hematology | 2025年6月 | C-CAR066, a novel fully human anti-CD20 CAR-T therapy for relapsed or refractory large B-cell lymphoma after failure of anti-CD19 CAR-T therapy: A phase I clinical study - DOI: 10.1002/ajh.27488 |
| LUPUS 2025 | 2025年5月22日 |
Clinical Impact of C-CAR168, a Novel Anti-CD20/BCMA Composite Autologous CAR-T Therapy, in Refractory Lupus Nephritis - 演示文稿幻灯片 C-CAR168, a novel dual-targeted cell therapy delivering immune system reset and new hope to refractory autoimmune diseases - 音频讨论 |
| The Blood | 2025年4月 | (C-CAR039) Prizloncabtagene autoleucel: a new CAR T cell for B-NHL - The Blood, Comment Article VOLUME 145, NUMBER 14 |
| The Blood | 2025年4月 | (C-CAR039) A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/ refractory B-cell non-Hodgkin lymphoma - The Blood, Regular Article VOLUME 145, NUMBER 14 |
| American College of Rheumatology (ACR) Convergence 2024 | 2024年11月16日 |
C-CAR168 as a Novel Anti-CD20/BCMA Bispecific Autologous CAR-T Therapy for the Treatment of Autoimmune Diseases |
| ASH Annual Meeting & Exposition | 2023年12月11日 |
C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up |
| 2023年12月9日 |
Two-Year Follow-up Results of C-CAR066, a Novel Anti-CD20 Chimeric Antigen Receptor Cell Therapy (CAR-T) in Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Patients after Failure of CD19 CAR-T Therapy |
|
| AACR Annual Meeting | 2023年4月14日 |
First report of preliminary safety, efficacy, and pharmacokinetics of C-CAR031 (GPC3-specific TGFβRIIDN CAR-T) in patients with advanced HCC |
| Journal for Immunotherapy of Cancer | 2022年9月 |
Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma |